teaser
The FDA has requested manufacturers of erythropoiesis-stimulating agents to add to the prescribing information for these drugs “black-box” warnings regarding a reduced survival rate when used in oncology patients.
According to a Reuters Health News report, the warning will state that the drugs shortened overall survival, or caused more rapid tumour growth, in clinical studies in patients with breast, non-small-cell lung, head and neck, lymphoid and cervical cancers, when given at high doses.
